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Background: Indirubin, isolated from the leaves of the Chinese herb Isatis tinctoria L, is a 
protein kinase inhibitor and promising antitumor agent. However, the poor water solubility of 
indirubin has limited its application. In this study, a supersaturatable self-microemulsifying 
drug delivery system (S-SMEDDS) was developed to improve the oral bioavailability of 
indirubin.
Methods: A prototype S-SMEDDS was designed using solubility studies and phase diagram 
construction. Precipitation inhibitors were selected from hydrophilic polymers according to their 
crystallization-inhibiting capacity through in vitro precipitation tests. In vitro release of indirubin 
from S-SMEDDS was examined to investigate its likely release behavior in vivo. The in vivo 
bioavailability of indirubin from S-SMEDDS and from SMEDDS was compared in rats.
Results: The prototype formulation of S-SMEDDS comprised Maisine™ 35-1:Cremophor® 
EL:Transcutol® P (15:40:45, w/w/w). Polyvinylpyrrolidone K17, a hydrophilic polymer, was 
used as a precipitation inhibitor based on its better crystallization-inhibiting capacity compared 
with polyethylene glycol 4000 and hydroxypropyl methylcellulose. In vitro release analysis 
showed more rapid drug release from S-SMEDDS than from SMEDDS. In vivo bioavailabil-
ity analysis in rats indicated that improved oral absorption was achieved and that the relative 
bioavailability of S-SMEDDS was 129.5% compared with SMEDDS.
Conclusion: The novel S-SMEDDS developed in this study increased the dissolution rate and 
improved the oral bioavailability of indirubin in rats. The results suggest that S-SMEDDS is a 
superior means of oral delivery of indirubin.
Keywords: supersaturatable self-microemulsifying drug delivery system, indirubin, 
bioavailability, oral drug delivery, hydrophilic polymer
Introduction
Indirubin (Figure 1) is a bisindole compound and protein kinase inhibitor, which is 
isolated from the leaves of the Chinese herb, Isatis tinctoria L. The drug has various 
pharmacological effects, including antitumor and anti-inflammatory activity.1–3 In the 
clinical setting, it has been shown to be effective in the treatment of chronic myelo-
cytic leukemia. In addition, indirubin has been shown to have marked antiproliferative 
activity and to be a strong inducer of apoptosis in multiple tumor cell types, including 
cervical cancer, liver cancer, and lymphoma cell lines.4 The reported mechanisms for 
the antitumor effect involve inhibition of DNA and protein synthesis and inhibition of 
key protein kinases.5 Long-term animal studies of indirubin have detected neither bone 
marrow toxicity nor hematotoxicity.6,7 However, indirubin has poor water solubility, 
resulting in low oral bioavailability. Moreover, ingestion often leads to irritation in the 
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gastrointestinal tract. Thus, although indirubin is a promising 
antitumor agent, its clinical use has been limited.8
Absorption of indirubin is reported to occur by passive 
diffusion. The transport of indirubin through the rat intestine 
membrane was not influenced by P-glycoprotein or by the 
multidrug resistance-associated protein.9,10 From the point of 
view of drug concentration, regardless of other issues, such 
as the size of the drug molecule and the absorptive surface 
area, the higher the drug concentration at the absorption 
site, the higher the fraction of absorbed drug transported 
by passive diffusion. Improved solubility and a higher dis-
solution rate for poorly water soluble drugs are key factors 
to enhance drug absorption.11 Thus, it is considered that 
improvement of indirubin bioavailability may be achieved 
by improving its solubilization in the gastrointestinal tract 
and increasing its dissolution rate in aqueous solution. Recent 
studies have focused on the development and evaluation 
of a self-emulsifying drug delivery system (SEDDS) for 
indirubin,12,13 in which indirubin has a 1.57-fold improve-
ment in bioavailability compared with commercial indirubin 
tablets in beagle dogs.
Over the last two decades, self-(micro)emulsifying drug 
delivery systems (SMEDDS) have been widely investigated 
as an effective means of delivering poorly water-soluble 
drugs via the oral route. The system is composed of oil, sur-
factant, and cosurfactant. An emulsion or microemulsion can 
be formed upon dispersion of SMEDDS in aqueous solution. 
However, when a drug is released from a microemulsion, 
precipitation often occurs due to decreased solubility, 
  leading to decreased drug dissolution and absorption in vivo. 
In addition, high amounts of surfactant and cosurfactant can 
generate side effects, including irritation of the gastrointes-
tinal tract, changes in intestinal membrane permeability, and 
toxicity.14,15 Nevertheless, significant amounts of surfactant 
and cosurfactant are required to deliver drugs in dissolved 
form. Thus, inhibiting drug precipitation upon mixing 
SMEDDS with aqueous solution is a key consideration in 
designing these formulations.
A supersaturation process can maintain drug solubiliza-
tion above equilibrium solubility without precipitation.16–19 
A high energy form of the drug (in comparison with crystal-
line powder) in solution yielded a supersaturated state with 
increased chemical potential. Thus, it is a thermodynamically 
unstable system. When a supersaturated drug delivery system 
exists at the absorption site for a sufficient period of time, the 
higher drug concentration generated from the supersaturated 
state may enhance drug absorption.20 Hydrophilic polymers 
such as hydroxypropyl methylcellulose (HPMC) and polyvi-
nylpyrrolidone (PVP) can be used in SMEDDS formulations 
as precipitation inhibitors to form supersaturatable self-
(micro)emulsifying drug delivery systems (S-SMEDDS). 
When S-SMEDDS come into contact with the aqueous 
environment of the gastrointestinal tract, the preparations 
are first emulsified, and an emulsion or microemulsion is 
formed immediately. The drug may be dissolved in free 
form or incorporated in emulsion or microemulsion droplets. 
Precipitation inhibitors may increase the solubility of the 
free drug or the drug in microemulsion and further increase 
the concentration gradient of the drug across the intestinal 
membrane, which may significantly improve the water solu-
bility of the drug and enhance oral absorption. Hence, more 
recently, S-SMEDDS have been developed to improve oral 
absorption of poorly water-soluble drugs.21–26 Generation 
of drug supersaturation in the gastrointestinal tract seems a 
promising way to improve the oral bioavailability of poorly 
water-soluble drugs.
The aim of this study was to develop an S-SMEDDS to 
improve the oral bioavailability of indirubin. First, proto-
type S-SMEDDS formulations were prepared. Hydrophilic 
polymers PVP, HPMC, and polyethylene glycol (PEG) 4000 
were used as precipitation inhibitors, and their crystallization-
inhibiting capacities were evaluated. The mechanism of 
inhibition of crystallization by the precipitation inhibitors 
was explored. Preparations were then assessed based on drug 
release and bioavailability.
Materials and methods
Materials
Indirubin was obtained from Nanjing Zelang   Medical 
  Technology Co Ltd, Nanjing, China. Glyceryl monoli-
noleate (Maisine™ 35-1), diethylene glycol monoethyl 
ether (  Transcutol® P), linoleoyl polyoxyl-6 glycerides 
(  Labrafil® M2125CS), medium-chain triglycerides (Labra-
fac™    Lipophile  WL1349)  and  caprylocaproyl 
H
O
N
H
HN
Figure 1 Chemical structure of indirubin.
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  macrogol-8   glycerides (  Labrasol®) were donated by 
Gattefossè, Gennevilliers, France. PEG 400, PEG 200, 
PEG 4000, and isopropyl myristate were purchased from 
Shanghai Chemical Reagent Corporation, Shanghai, 
China. Olive oil was sourced from Sictia, Marseille, 
France. Caprylic/capric triglyceride (GTCC) was obtained 
from Guangdong Indwell Industrial and Trading Co, 
Ltd, Guangdong, China. Polyoxyl 40 hydrogenated cas-
tor oil (Cremophor® RH 40), polyoxyl castor oil (Cre-
mophor EL), and povidone K17 (PVP K17) were from 
BASF, Ludwigshafen, Germany. Methocel E6 premium 
HPMC was purchased from Colorcon, Shanghai, China. 
The other chemicals were of analytical grade.
Solubility studies
The solubility of indirubin in various oils, surfactants, and 
cosurfactants was determined as follows. Vehicle (1 g) was 
added to capped tubes containing an excess of indirubin. 
After the test tubes were sealed, the mixtures in the test 
tubes were shaken for 72 hours at 100 strokes per minutes 
in a water bath maintained at 25°C, and the tubes were 
then centrifuged at 6700 g for 5 minutes. The supernatant 
was dissolved in ethyl acetate in a volumetric flask, and 
methanol was added to make up the volume. After filtra-
tion through a 0.45 µm membrane filter, the concentration 
of indirubin was determined by HPLC. HPLC analysis was 
carried out using a LC-2010A HT liquid chromatography 
system (Shimadzu Corporation, Kyoto, Japan) as follows: 
Kromasil®-5C18 column (250 mm × 4.6 mm, 5 µm); mobile 
phase of methanol:water:phosphoric acid (90:10:0.1, v/v/v); 
column temperature of 40°C; detection wavelength 225 nm; 
flow rate of 1 mL/minute.
Phase diagram construction
The ternary phase diagrams of mixtures of oil, surfactant, and 
cosurfactant at certain ratios were constructed as previously 
described.27 After dilution and gentle agitation of the mixtures 
in simulated gastric fluid, the emulsification behavior was 
observed. The boundaries of the self-microemulsification 
regions in the phase diagrams were determined by connecting 
the points representing formation of the microemulsion.
Preparation of SMEDDS
The compounds used in the indirubin SMEDDS formulations 
are shown in Table 1. Indirubin were prepared by dissolving 
the drug in the mixture of Transcutol P, Cremophor EL, and 
Maisine 35-1 with continuous stirring. SMEDDS was formed 
when the dispersion became transparent. PVP K17 was then 
introduced into the SMEDDS preparation and dispersed by 
vortexing.
Determination of droplet size  
and zeta potential
Formulations were diluted in distilled water before analysis. 
Droplet size and distribution was measured by photocorrela-
tion spectroscopy using a Nicomp 380/ZLS system (PSS, Port 
Richey, FL). Each sample was analyzed in triplicate. Zeta 
potential was determined in the same manner.
In vitro evaluation of precipitation
To investigate the precipitation-inhibiting capacity of hydro-
philic polymers, in vitro precipitation assays were conducted 
using a RC 806 dissolution tester (Tianjin Tianda Tianfa 
Technology Co, Ltd, Tianjin, China) with 250 mL round 
vessels at 37°C ± 0.5°C and a stirring speed of 100 rpm. The 
formulations including SMEDDS and SMEDDS containing 
various hydrophilic polymers were mixed with simulated 
gastric fluid to a total volume of 100 mL. At predetermined 
times, 0.5 mL of sample was withdrawn and centrifuged at 
13,000 rpm for 3 minutes. Supernatant (0.2 mL) was mixed 
with 0.4 mL of methanol, and the concentration of indirubin 
was analyzed by HPLC.
In vitro release
In vitro release assays were carried out according to the 
release test method described in the Chinese Pharmacopeia 
(2010 edition, small cup method).28 Indirubin S-SMEDDS 
(0.5 g) was added to a size zero capsule. The capsule was 
then put into the basket in 100 mL of simulated gastric fluid. 
Samples (0.5 mL) were removed at 5, 10, 20, 30, 40, 60, 
120, 180, 240, and 420 minutes after addition of drug, and 
the volume was replaced by adding 0.5 mL of fresh medium. 
Table 1 Solubility of indirubin in various vehicles at 25°C
Vehicles Solubility (μmoL/g)
Oils Olive oil 0.145
IPM 0.087
GTCC 0.154
Labrafil M2125CS 0.338
Labrafac Lipophile WL1349 0.159
Maisine 35-1 0.755
Surfactants Cremophor RH40 0.631
Cremophor EL 1.305
Cosurfactants Transcutol P 1.356
PEG 400 0.143
PEG 200 0.093
Abbreviations:  PEG,  polyethylene  glycol;  GTCC,  caprylic/capric  triglyceride; 
IPM, isopropyl myristate.
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The indirubin concentration was measured as described 
above. The cumulative released percentage was calculated 
as shown in Equation 1:
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in which Q is the cumulative percentage released; Ct is the 
indirubin concentration at time t; V represents the volume of 
release medium (V = 100 mL); V a is the volume of sampling 
aliquot (V a = 0.5 mL); and W is the initial amount of indirubin 
in the capsule.
Bioavailability study
The animal experiments were approved by the institu-
tional animal ethics committee of Shanghai University 
of Traditional Chinese Medicine. Male Sprague-Dawley 
rats (weight 200 ± 20 g) were divided into three groups 
of six animals. Prior to drug administration, the animals 
were fasted for 12 hours with free access to water. The 
tested preparations were SMEDDS, S-SMEDDS, and 
the suspensions. SMEDDS was prepared using the same 
method as described for preparation of S-SMEDDS but with 
PVP K17 omitted. Suspensions were prepared by dispers-
ing indirubin in sodium carboxymethyl cellulose solution 
with glycerin as a wetting agent. Rats were administered 
a indirubin dose of 2.58 mg/kg for each preparation by 
gavage, followed by 1 mL of physiological saline. Blood 
samples (0.5 mL) were collected into heparinized tubes 
via retro-orbital puncture at hours 0.5, 1, 2, 3, 4, 5, 6, 8, 
10, 12, and 24 post dose. Blood samples were centrifuged 
at 2000 g for 5 minutes. Plasma was kept at −20°C until 
analysis, as described below.
A 0.2 mL sample of plasma was mixed with an equal 
volume of saturated ammonium sulfate solution and vortexed 
for 10 seconds. Ethyl acetate (0.6 mL) was added, and the 
mixture was vortexed for 3 minutes. After centrifugation at 
10,000 rpm for 3 minutes, the upper layer was removed and 
dried under gentle flowing nitrogen. Residuals were reconsti-
tuted in 100 µL of methanol. The mixture was vortexed for 
20 seconds and then centrifuged at 13,000 rpm for 3 minutes. 
The supernatant was used for content analysis.
Indirubin concentrations in rat plasma were determined 
using a Waters Acquity UPLC-Micromass ZQ 2000 system 
(Waters Corporation, Milford, MA). An Acquity UPLC 
R BEH C18 column (1.7 µm, 2.1 × 50 mm) was used at 
30°C. The mobile phase A was 0.1% formic acid in water. 
The mobile phase B was methanol. The gradient program was 
set as follows: 0–6 minutes: 40% A, 60% B; 6–7 minutes: 
10% A, 90% B; 7–9 minutes: 40% A, 60% B. The flow rate 
of the mobile phase was kept at 0.3 mL/minute. The injection 
volume was 10 µL. Triple-quadruple tandem mass spectro-
metric detection was operated in positive ionization mode 
with m/z of 262.3, a source temperature of 120°C, capillary 
voltage of 3000 V , desolvation flow rate of 500 L/hour, and 
desolvation temperature of 250°C.
Data analysis
Pharmacokinetic parameters were obtained using DAS 
2.0 software. Statistical analysis for the pharmacokinetic 
parameters was carried out using one-way analysis of vari-
ance. A P value of ,0.05 was considered to be statistically 
significant.
Results and discussion
SMEDDS formulation
Initially, SMEDDS were developed as prototypes of 
S-SMEDDS. To obtain a SMEDDS formulation, we deter-
mined the solubility of indirubin in various oils, surfactants, 
and cosurfactants. The results are presented in Table 1. The 
solubility of indirubin in the tested oils, in decreasing order, 
was as follows: Maisine 35-1 . Labrafil M2125CS . 
Labrafac Lipophile WL1349 . GTCC . olive oil . 
isopropyl myristate. Solubility of indirubin in Cremophor 
EL (surfactant) and Transcutol P (cosurfactant) was mark-
edly higher than in other vehicles, indicating superior dis-
solving capability for indirubin. Based on these results, we 
selected Maisine 35-1 for the oil phase, Cremophor EL as the 
surfactant, and Transcutol P as the cosurfactant for further 
investigation.
A phase diagram was constructed to identify the self-
microemulsification regions. A series of formulations 
containing Maisine 35-1, Cremophor EL, and Transcutol 
P were prepared and diluted 200-fold in simulated gastric 
fluid at 37°C. A dispersion with a transparent appearance 
was regarded as a microemulsion. The phase diagram is 
shown in Figure 2.
Based on analysis of self-microemulsifying regions, 
three formulations were selected for further assessment of 
droplet size, polydispersibility, and equilibrium solubility. 
As shown in Table 2, the droplet size of formulation C was 
clearly smaller than that of the other formulations. In addi-
tion, formulation C had better solubilizing capacity than 
the other formulations. In a previous study, we found that 
both the oil percentage and surfactant to cosurfactant ratio 
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influence equilibrium solubility.29 As shown in Table 1, the 
Transcutol P cosurfactant had better dissolving capability 
for indirubin than Cremophor EL. This may explain the fact 
that when the oil percentage was the same, formulation C 
(with higher Transcutol P content) exhibited better drug 
solubility than the other two formulations. Based on these 
findings, formulation C was selected as the final prototype 
S-SMEDDS.
Screening for a precipitation inhibitor
A hydrophilic polymer is an essential excipient in a 
S-SMEDDS formulation. Hydrophilic polymers, such as 
PVP, HPMC, and PEG, have been found to be useful as 
precipitation inhibitors.18,30–34 In this study, HPMC, PEG 
4000, and PVP K17 were assayed for inhibition of crystal-
lization in vitro.
As reported previously, evaluation of the true free drug 
concentration in preparations dispersing in aqueous sys-
tems is difficult, mainly due to the complex drug state and 
dynamic processes during dispersion.21–23 When SMEDDS 
is dispersed into aqueous solution, the drug may exist in 
three main states, namely, as a free molecule in solution, 
solubilized in microemulsion or similar vehicles, and/or 
precipitated as solid particles. To evaluate drug precipitation 
behavior accurately, it is important to separate precipitated 
drug from the dispersion system upon mixing SMEDDS with 
an aqueous solution. Syringe filters method and centrifuga-
tion method are generally used methods.24,25,35 The syringe 
filter method may separate a solution with precipitated drugs 
by filtration, and the centrifugal method achieves separation 
by centrifugation. In addition, Gao et al reported an improved 
approach using focused beam reflectance measurement 
technology.23 Their method is a fast and convenient in situ 
measurement technology that may detect particles within 
the size range of 1–1000 µm.23 However, it was noted 
that focused beam reflectance measurement cannot detect 
particles less than 1 µm in size. In this study, we compared 
membrane filtration and centrifugation by evaluating the 
recovery and repeatability of each method. We found that 
the centrifugation method yielded higher recovery and 
repeatability than filtration, perhaps by eliminating loss by 
adsorption to the filter (data not shown). It should also be 
noted that in addition to free molecules in solution and solu-
bilized drug in microemulsion or other vehicles, nanosized 
solid drug particles may also be present in supernatants 
after centrifugation.
The indirubin concentrations in simulated gastric fluid 
after dilution of SMEDDS (without hydrophilic polymers) 
and S-SMEDDS formulations are shown in Figure 3. 
  Figure 3A shows the indirubin concentration-time profile 
using varying amounts of PEG 4000 as a precipitating 
inhibitor. The results indicate that the formulation with 2% 
PEG 4000 achieved the highest drug concentration compared 
with the other formulations. PEG 4000 was finely dissolved 
in SMEDDS, but as the amount of PEG 4000 increased, the 
dispersions became increasingly viscous. At 5% PEG 4000, 
the dispersions became gel-like due to high viscosity, which 
may hinder self-microemulsification.
In the case of HPMC, compared with HPMC-free 
SMEDDS, there was no marked enhancement of drug 
release in the presence of 0.5%, 2%, and 5% HPMC 
(Figure 3B). This result indicated that HPMC appeared 
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Figure 2 Ternary system containing Maisine 35-1/Cremophor EL/Transcutol P. 
Region of efficient self-microemulsification is bound by the solid line, and the filled 
circles represent compositions that were evaluated.
Table 2 Droplet size, polydispersibility, and solubility for the three tested SMEDDS formulations
Formulation composition  
(Maisine 35-1:Cremophor EL:Transcutol P, w:w:w)
Droplet size (nm) Polydispersibility Solubility (μg/g)
A 15:50:35 93.62 0.284 424.3
B 15:30:55 91.38 0.524 437.9
C 15:40:45 22.17 0.193 474.8
Abbreviation: SMEDDS, self-microemulsifying drug delivery system.
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less effective as a precipitation inhibitor. As shown in 
  Figure 3C, the   highest release was achieved when 0.5% 
PVP K17 was used. In addition, PVP K17 was well 
dispersed in SMEDDS, and the addition of PVP K17 to 
SMEDDS had no significant influence on the viscosity of 
the dispersions. Based on these results, we concluded that 
the precipitation-inhibiting capacity of the three hydro-
philic polymers was in the order PVP K17 . PEG 4000 . 
HPMC, and that 0.5% PVP K17 can efficiently retard 
precipitation and maintain a higher indirubin concentra-
tion for approximately 2 hours or longer.   Therefore, 0.5% 
of PVP K17 was selected to add to SMEDDS. The final 
S-SMEDDS formulation   composition was Maisine 
35-1:Cremophor EL:Transcutol P 15%:40%:45% (w/w/w) 
with 0.5% PVP K17.
The indirubin molecule is formed using a π-conjugated 
system. There are strong hydrogen bonds between an oxy-
gen atom and adjacent hydrogen atom. Hydrogen bonds are 
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Figure 3 In vitro indirubin concentration-time profiles from the SMEDDS formulations and S-SMEDDS with hydrophilic polymers of (A) PEG 4000, (B) HPMC, and (C) PVP 
K17 (n = 5).
Abbreviations: SMEDDS, self-microemulsifying drug delivery system; S-SMEDDS, supersaturatable self-microemulsifying drug delivery system; PEG, polyethylene glycol; 
PVP, polyvinylpyrrolidone; HPMC, hydroxypropyl methylcellulose.
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responsible for the stability of the molecule. One hexatomic 
ring can be formed by intramolecular hydrogen bonds, 
and therefore lower the ring strain and the molecular total 
system energy.36  Therefore, the indirubin molecule is stable 
and has low water solubility. We found that both PEG 4000 
and indirubin were well dissolved in SMEDDS. We propose 
that when each PEG 4000 molecule (Figure 4A) opened the 
two parallel helical bonds, the indirubin molecules were 
incorporated into the coiling chain to cause molecular 
dispersion. Meanwhile, the intramolecular hydrogen bond 
was activated upon dissolving of indirubin in SMEDDS, 
and exchanging of a hydrogen bond with PEG 4000 may 
occur (Figure 4D). In a previous report, it was proposed 
that the adsorption of the polymer onto the crystal surface 
may play a role in inhibition of crystallization, caused by 
a hydrogen bond between the drug and the hydrophilic 
polymer.37–39 Therefore, from this perspective, the hydrogen 
bonds between indirubin and PEG 4000 may contribute 
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Figure 4 Molecular structures of (A) PEG 4000, (B) PVP, (C) HPMC and schematic diagram of hydrogen bonds between indirubin, (D) PEG 4000, and (E) PVP.
Abbreviations: PEG, polyethylene glycol; PVP, polyvinylpyrrolidone; HPMC, hydroxypropyl methylcellulose.
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to the retarded precipitation of indirubin after dilution of 
SMEDDS.
Another factor responsible for the role of the precipita-
tion inhibitor is thought to be the incorporation of drug 
molecules into polymer aggregates.40 In the case of PVP K17 
(Figure 4B), after PVP K17 and indirubin were dissolved 
in SMEDDS, PVP K17 showed reticulate structures, and 
indirubin molecules may be incorporated into the reticulate 
structures resulting in molecular dispersion. Indirubin-PVP 
K17 hydrogen bonds were formed between the carbonyl 
group of the pyrrolidone ring of PVP K17 and the amino 
group in the pyrrole ring as well as the amido hydrogen of 
indirubin (Figure 4E). Hydrogen bonding and incorporation 
of indirubin into reticulate structures, as well as high viscos-
ity, may efficiently inhibit the aggregation and crystallization 
of indirubin. Further study of the indirubin-PVP K17 interac-
tion using infrared spectroscopy or other analytic strategies 
may clarify these matters.
HPMC (Figure 4C), a cellulosic polymer, has been 
reported to be an efficient crystal growth inhibitor for many 
drugs in aqueous dispersions.18,33,39 Approximately 60% of 
the hydroxyl groups in HPMC are not substituted. HPMC 
can thus form both intramolecular and intermolecular 
hydrogen bonds. Thus, HPMC is more hydrophobic than 
PVP K17 and PEG 4000. Once the hydrogen bonds are 
disrupted in the dissolved state, HPMC may interact with a 
drug and form hydrogen bonds, which is likely to retard drug 
precipitation. Furthermore, based on the molecular struc-
ture, HPMC may provide more hydrogen bonding groups 
per monomer unit compared with PVP K17. (Interaction 
of indirubin and HPMC is not described herein due to the 
complex substituent group leading to uncertain hydrogen 
bond formation). However, in this study, we found that 
HPMC cannot be dissolved in indirubin SMEDDS. Thus, 
it appears that HPMC exerted no precipitation-inhibiting 
action on indirubin SMEDDS.
In vitro release study
The in vitro release assay (Figure 5) showed that 70% of 
the drugs was released from S-SMEDDS in 60 minutes, 
while approximately 50% of the drugs was released from 
SMEDDS in 120 minutes. S-SMEDDS exhibited faster 
release behavior than SMEDDS. However, the percentage 
released in the case of S-SMEDDS decreased slightly after 
60 minutes, and decreased slowly to approximately 60% at 
240 minutes. The released drug was detected in the dissolved 
form either in solution or in the microemulsion-like vehicles. 
Thus, the decrease in the amount of dissolved drug indicated 
that precipitation had occurred. A supersaturatable system 
is thermodynamically unstable, and a supersaturatable drug 
solution has a tendency to return to its equilibrium state via 
drug precipitation.20 Thus, the supersaturation process may 
only keep the drug dissolved for a limited period of time. 
With increasing time, drug precipitation may occur, which 
results in a decreased amount of dissolved drug. Because 
there is no supersaturation process involved in SMEDDS, 
the percentage of drug released increased steadily with the 
passage of time. Almost the same percentage of drug release 
was achieved for the two preparations at 420 minutes. Based 
on the results of our in vitro release study, we surmise that 
S-SMEDDS would have higher bioavailability in vivo than 
SMEDDS.
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Bioavailability study
Ultra performance liquid chromatography/mass spectrom-
etry chromatograms are shown in Figure 6, which indi-
cate that endogenous substances in plasma did not affect 
detection of indirubin. Figure 7 shows the mean plasma 
concentration profile of indirubin from the suspension, 
SMEDDS, and S-SMEDDS after oral administration to 
rats. The plasma concentration of indirubin after dosing of 
the indirubin suspension could not be detected due to poor 
oral absorption in vivo. S-SMEDDS containing indirubin 
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Figure 6 Ultra performance liquid chromatography/mass spectrometry chromatograms of (A) blank plasma, (B) blank plasma spiked with indirubin, and (C) plasma sample 
after oral administration of indirubin to a rat.
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provided higher plasma drug concentrations than SMEDDS 
containing indirubin.
Mean area under the curve (AUC), peak plasma 
concentration, and relative bioavailability are listed in 
Table 3. Parameters for the suspensions were not analyzed 
because the plasma concentration could not be detected. 
The relative bioavailability was calculated by dividing 
AUC0–24 h (S-SMEDDS) by AUC0–24 h (SMEDDS). The 
peak plasma concentration and mean residence time values 
for indirubin from S-SMEDDS were not significantly dif-
ferent than those from SMEDDS. However, the AUC for 
S-SMEDDS was significant larger than that of SMEDDS 
(P , 0.05).
These results suggest that S-SMEDDS might be useful 
for enhancing the oral absorption of indirubin. Furthermore, 
the results of the in vivo bioavailability study appear to cor-
relate with those of the in vitro release study, which indicates 
a faster release rate from S-SMEDDS than from SMEDDS. 
For poorly water soluble drugs, dissolution is generally the 
rate-limiting step to drug absorption. A higher release rate 
might play an important role in enhancing bioavailability. In 
addition, S-SMEDDS provides indirubin in supersaturated 
conditions upon mixing with aqueous dispersions, allowing 
indirubin to dissolve rather than precipitate, and further 
enhancing bioavailability.
Conclusion
The novel S-SMEDDS developed in this study increased 
the dissolution rate and improved the oral absorption of 
indirubin. The S-SMEDDS is a promising way to deliver 
indirubin by the oral route.
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